Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

Ben Zeskind, Ph.D., CEO of Immuneering

“We are thrilled to share that follow-up in our Phase 2 trial in first-line pancreatic cancer is being extended because patients are living longer than projected. We now plan to provide an update on topline data from the atebimetinib + mGnP arm of that trial in the first half of 2027. We are also excited to report that enrollment in our pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule. This strong momentum enables us to expand the enrollment target and potentially accelerate our expected mid-2028 topline data readout. We have updated our cash runway guidance to the fourth quarter of 2028 to reflect our Phase 2 extension, accelerated and expanded Phase 3 enrollment, and commercial readiness activities.”

Ben Zeskind, Ph.D., CEO of Immuneering

“We are seeing growing recognition within the medical community of atebimetinib’s differentiated mechanism of action as demonstrated by the strong engagement with our presentations at recent medical meetings, including the 2026 AACR Conference on Pancreatic Cancer and ESMO Congress 2026. The 17.3 months median overall survival with excellent tolerability that we reported at ASCO is unprecedented among agents targeting this pathway, and we are excited to share updated clinical data in the first half of 2027.”